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Abstract
Progressive liver fibrosis is characterized by the deposition of collagen by activated hepatic 
stellate cells (HSCs). Activation of HSCs is a multiple receptor-driven process in which 
profibrotic signals are enhanced, and anti-fibrotic pathways are suppressed. Here we report the 
discovery of a novel signaling platform comprised of G protein subunit, Gαi and GIV, its guanine 
exchange factor (GEF), which serves as a central hub within the fibrogenic signalling network 
initiated by diverse classes of receptors. GIV is expressed in the liver after fibrogenic injury and is 
required for HSC activation. Once expressed, GIV enhances the profibrotic (PI3K-Akt-FoxO1 and 
TGFβ-SMAD) and inhibits the anti-fibrotic (cAMP-PKA-pCREB) pathways to skew the 
signalling network in favor of fibrosis, all via activation of Gαi. We also provide evidence that 
GIV may serve as a biomarker for progression of fibrosis after liver injury and a therapeutic target 
for arresting and/or reversing HSC activation during liver fibrosis.
Introduction
Liver fibrosis is the consequence of an excessive deposition of collagen resulting from an 
imbalance between its synthesis and degradation. Upon liver injury, hepatic stellate cells 
(HSCs), the major collagen-synthesizing cells in the liver, become activated and 
transdifferentiate into myofibroblast-like cells which proliferate faster and display enhanced 
chemotaxis, survival and collagen production 1. Such transdifferentiation is triggered by the 
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activation of a diverse classes of receptors, e.g., PDGFR 2, TGFβR 3, EGFR 4, VEGFR 5, 
IR/IGF1R 6, Gi-coupled chemokine/cytokine receptors (CCRs) 7 and Toll-like receptor 4 
(TLR4) 8, and two of them (TGFβR and PDGFR) have been widely studied and established 
as major pro-fibrogenic receptors 2,3. Regardless of the type of receptor activated, two key 
profibrotic signals, the PI3K-Akt and the SMAD signaling cascades 9, must be enhanced to 
initiate and propagate HSC activation and collagen synthesis. Once activated, the PI3K-Akt 
pathway triggers fibrogenesis via 3 mechanisms-- 1) by inactivating Forkhead box protein 
O1 (FoxO1), an anti-fibrotic transcription factor that suppresses transdifferentiation and 
proliferation of HSCs 10, 2) by suppressing apoptosis 11, and 3) by further enhancing the 
TGFβ-SMAD-collagen pathway 11. Although widely recognized as a key profibrotic trigger, 
the precise multi-receptor mediated mechanism(s) that drives unrestricted enhancement of 
the PI3K-Akt pathway remains elusive.
Profibrotic pathways are antagonistically balanced by cyclic adenosine monophosphate 
(cAMP), a well known and conserved antifibrotic signaling second messenger of G protein 
signaling cascades 12. Accumulation of cAMP in HSCs is known to inhibit chemotaxis, 
proliferation, and collagen synthesis, while simultaneously increasing the removal of 
collagen by metalloproteases 13. Mechanistically, cAMP inhibits TGFβ-SMAD signaling at 
a transcriptional level via modulation of the protein kinase A (PKA)-cAMP response 
element binding protein (CREB)-dependent pathway 14. Although recognized as a key 
antifibrotic signal, the mechanism(s) by which cAMP levels are suppressed by multiple 
receptors during liver fibrosis remains unknown.
We recently established that GIV, a.k.a Gα-Interacting Vesicle-associated protein is a 
multimodular signal transducer and a guanine nucleotide exchange factor (GEF) for trimeric 
Gi that modulates key signaling events downstream of diverse classes of receptors, e.g., 
growth factor receptor tyrosine kinases (RTKs), e.g., EGFR, IGF1R, VEGFR and InsR 15-18 
and chemotactic G protein-coupled receptors (GPCRs) like LPAR1 16,19,20. Working 
downstream of both RTKs and GPCRs, GIV serves as a common platform that enhances 
PI3K-Akt signals and reduces cAMP production, all via activation of Gi 16. GIV modulates 
signaling during diverse biological processes including epithelial wound healing, 
macrophage chemotaxis, development, autophagy, angiogenesis, vascular repair and tumor 
metastasis (reviewed in ref 21).
Because signaling pathways modulated by GIV are also major components of the fibrogenic 
network, here we investigated if GIV plays a role in the activation of HSCs during liver 
fibrosis. We found that GIV triggers HSC activation by coordinately reshaping the 
fibrogenic signaling network (enhances pro- and inhibits anti-fibrogenic signals) 
downstream of multiple receptors, all via activation of Gαi. Because the fundamental 
signaling pathways driven by GIV are common to fibrogenic diseases afflicting other 
organs, insights gained will impact the understanding, approach, and the paradigms of 
diverse fibrosis-related diseases.
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Results
GIV expression is upregulated in liver after fibrotic injury
We previously showed that expression of GIV is upregulated during epithelial wound 
healing 22. Because liver fibrosis in response to chronic injury mimics the process of wound 
healing 23, we asked whether the level of GIV expression is altered during the course of 
chronic liver injury in patients with chronic HCV hepatitis, a leading cause of liver 
cirrhosis 24. We found that full-length GIV mRNA was virtually undetectable in normal 
livers, but elevated ~50 fold in livers with mild to moderate fibrosis (Ishak score 1-4), and 
~175 fold in those with cirrhosis (Ishak scores 5, 6) (Figure 1A), indicating that GIV 
mRNA expression increases with increasing degree of liver fibrosis. When we analyzed 
liver samples from two well-accepted animal models for chronic liver injury 25, i.e., surgical 
bile duct ligation (BDL) and chronic injection of carbon tetrachloride (CCl4) we found that 
GIV mRNA was virtually undetectable in normal murine livers (sham and vehicle controls), 
but elevated ~15-45 fold in response to both types of injuries during progressive fibrosis 
(Figure 1B, 1C). Next we analyzed total liver lysates from BDL or CCl4-treated mice for 
GIV protein expression by immunoblotting with an antibody that recognizes the C-terminus 
of full-length GIV (CT-Ab) 26. GIV was detected exclusively after injury in both study 
models, increasing with progressive fibrosis (Figure 1D, 1E, Supplementary Fig. 1A), and 
such expression correlated with increased activation of the PI3K-Akt pathway, as 
determined by Akt phosphorylation (Figure 1D, 1E). GIV was also detected by 
immunohistochemistry (IHC) in mice livers exclusively after BDL or CCl4- injury (Figure 
1F), and in liver biopsies from patients with liver fibrosis due to a variety of chronic injuries 
(Figure 1G). The staining pattern in injured livers was consistent with restricted expression 
of full-length GIV exclusively in non-parenchymal i.e., interstitial cells, whereas 
hepatocytes, which comprise ~85% of the total cell mass of the liver, do not express full-
length GIV regardless of injury. These findings indicate: 1) that there is little or no 
expression of full-length GIV (neither mRNA nor protein) in normal livers; 2) that GIV 
expression is consistently induced after a variety of chronic injuries; 3) that the abundance 
of GIV mRNA increases with progressive fibrosis; 4) that the increase in mRNA is 
accompanied by translation of GIV protein; and 5) that increased GIV protein expression 
correlates with increased Akt activation in the injured livers.
Unlike chronic injuries, when microarrays performed on a variety of acute liver injuries 
were analyzed for the expression profile of GIV, we found that GIV expression was elevated 
in some, but not all cases (Supplementary Fig. 1B-E). GIV mRNA was minimally 
upregulated in patients with acute viral hepatitides (Supplementary Fig. 1B, C), which 
carries the potential of progressing to chronicity and liver fibrosis in some patients, whereas 
no such upregulation was observed in acute alcoholic hepatitis or in a murine model of acute 
injury by partial hepatectomy (Supplementary Fig. 1D, E), two conditions that heal without 
fibrosis 27. These findings indicate that GIV expression is induced during some, but not all 
injuries of the liver, and that persistent upregulation of GIV expression is primarily 
restricted only to chronic injuries of the liver.
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GIV expression is upregulated in activated HSCs
To determine which non-parenchymal cell type within the liver contributes to the observed 
increase in GIV we carried out liver cell fractionation from BDL-treated and control mice, 
and analyzed the isolated cell types for expression of GIV mRNA. Consistent with our IHC 
staining pattern, we found that hepatocytes have no detectable full-length GIV transcript 
regardless of injury (Figure 2A). Low levels of GIV mRNA were detected in all the other 
cells isolated from control livers, which significantly increased after BDL. Both HSCs and 
Kupffer cells (KCs; the liver resident macrophages), which drive liver fibrosis in response to 
chronic liver injury 28, showed significant increases after injury. We focused on the role of 
GIV expression in HSCs for two outstanding reasons: 1) they contribute to ~80% collagen 
produced during liver fibrosis, and 2) they are the final common target of cytokines and 
growth factors produced by other cells that contribute to liver fibrosis, e.g., KCs and 
sinusoidal endothelial cells (ECs) 28,29. When we quantitatively assessed GIV mRNA in 
isolated HSCs after BDL or CCl4 injuries, we found, similar to our results in whole liver, 
that expression of full-length GIV is upregulated ~2-4 fold during progressive fibrosis in 
both models of chronic injury (Figure 2B, 2C).
To further corroborate whether GIV protein is expressed in HSCs after chronic liver injury 
we analyzed the expression of full-length GIV in situ in semi-thin sections of livers 
harvested from control and CCl4-treated Col-GFP mice by immunofluorescence. We used 
Col-GFP transgenic mice that express GFP driven by alpha1 (I) collagen promoter 30 
because, in these mice, GFP serves as a surrogate marker for collagen expression in whole 
liver extracts and in isolated primary HSCs 30. As anticipated, GFP (collagen) and α-
Smooth muscle actin (α-SMA), a bona fide marker for active HSCs 31 were detected 
exclusively after injury. GIV was undetectable in the control liver, but detected in activated 
HSCs, as determined by colocalization with α-SMA (Figure 2D). Expression of GIV 
correlated with collagen (GFP) expression in these α-SMA-positive HSCs (arrowheads in 
Figure 2D), indicating that upon injury, expression of GIV protein coincides with HSC 
activation and collagen synthesis. GIV was also detected at lower levels in α-SMA-negative 
cells that are likely to be ECs or KCs (stars in Figure 2D). Together these results 
demonstrate that GIV mRNA is upregulated in HSCs after injury and GIV protein is 
translated after HSC activation.
Expression of GIV precedes collagen synthesis during HSC activation
Next we investigated the temporal correlation between GIV expression, HSC activation (as 
determined by α-SMA expression) and collagen production in HSCs isolated from Col-GFP 
mice. HSCs were activated on plastic culture dishes and monitored for morphologic changes 
that are characteristic of transdifferentiation and by the abundance of collagen (GFP) 
synthesis (Supplementary Fig. 2). On day 1, as expected, inactive HSCs contained lipid 
droplets laden with retinyl esters and did not express collagen, however, ~50% of those 
collagen-negative cells already expressed GIV (Figure 3A). Both GIV and collagen 
expression increased robustly in all HSCs on days 3, 5 and 7. Noteworthy, there were no 
collagen positive HSCs that did not also express GIV, indicating that GIV expression 
invariably preceded expression of collagen. An analysis of mRNA levels confirmed that 
induction of GIV expression precedes collagen and α-SMA expression (Figure 3B-E) 
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during HSCs activation; while GIV expression peaks on day 1 expression of collagen and α-
SMA peak on day 3. These results demonstrate that in HSCs activated ex vivo, upregulation 
of GIV is likely to be an upstream event which precedes HSC activation and collagen 
synthesis.
GIV is required for activation of HSCs
HSC activation is characterized by key phenotypes such as enhanced proliferation, cell 
migration, actin remodeling, resistance to apoptosis and collagen production 1. Next we 
asked if GIV is required for some or most of these phenotypes, and thereby, for HSC 
activation. First, we analyzed GIV expression, localization and properties in cultured human 
Lx2 HSC line, which has been extensively characterized and widely accepted as a model 
system to study fibrogenic pathways 31. We found that Lx2 cells express GIV as a ~250 kDa 
full-length protein (Figure 4A) which localizes to the Golgi and PM-associated actin bed 
(Supplementary Fig. 3A), as previously shown in other cell lines 19,32. Similar localization 
was also observed in primary murine HSCs (Supplementary Fig. 3A). Compared to control 
cells, GIV-depleted cells (~85-90% efficacy; Figure 4A) showed fewer actin stress fibers 
(Figure 4B), impaired cell migration (Figure 4C, Supplementary Fig. 3B), and suppressed 
mitosis, as determined by nuclear accumulation of phospho-histone H3 (Figure 4D, 
Supplementary Fig. 3C) and by BrDU uptake (Figure 4E, Supplementary Fig. 3D). 
These results demonstrate that GIV is required for cell migration, proliferation and 
cytoskeletal remodeling in HSCs.
Because activated HSCs acquire resistance to apoptosis 1 we analyzed the expression of two 
bona fide pro- (Bax) and anti- (Bcl-2) apoptotic signaling intermediates 33. In GIV-depleted 
HSCs, proapoptotic Bax was upregulated ~2 fold (Figure 4F) and anti-apoptotic Bcl-2 was 
decreased by ~40% (Figure 4G) compared to controls, indicating that in the absence of GIV 
cells are overall pro-apoptotic. Moreover, in HSCs treated with gliotoxin 34, an inducer of 
apoptosis, GIV expression was reduced by ~50%, alongside the expected increase of Bax 
and decrease in Bcl-2 (Supplementary Fig. 3E), indicating that changes in GIV expression 
profile after a pro-apoptotic injury mirrors that of an anti-apoptotic gene, i.e., Bcl-2, and not 
Bax. To confirm GIV's anti-apoptotic role in HSCs we carried out TUNEL assays and 
analyzed cleavage of Caspase 3, two widely used approaches for measuring cellular 
apoptosis35. We found that compared to control cells, GIV-depleted cells had increased 
Caspase 3 activity, as determined by the presence of the cleaved enzyme (Figure 4H; ~ 2.5 
fold) and increased, fragmented DNA, as determined by TUNEL (Figure 4I; ~ 2.5 fold). 
These results demonstrate that depletion of GIV triggers apoptosis, and that GIV is required 
for survival of HSCs after injury.
Because GIV modulates signal transduction primarily via its GEF property 16 we asked if 
two key HSC phenotypes, i.e., proliferation and collagen production requires GIV's GEF 
function. To investigate this, we took advantage of previously validated GIV constructs: 
wild-type GIV (GIV-WT), and GEF-deficient F1685A (GIV-FA) mutant 16. Depletion of 
GIV from Lx2 HSCs suppressed collagen production in response to transforming growth 
factor-β1 (TGF-β1) by ~40-50% compared to controls (Figure 4J), an effect that was 
reversed by exogenous expression of siRNA-resistant GIV-WT, but not GIV-FA mutant. 
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Similar results were obtained also in TGF-β1-stimulated primary HSCs, i.e., expression of 
GIV-FA suppressed collagen synthesis by ~60% compared to GIV-WT (Figure 4K). 
Finally, with regard to mitogenic response to platelet-derived growth factor (PDGF), 
expression of GIV-FA suppressed mitosis by ~7 fold compared to GIV-WT (Figure 4L), 
indicating that GIV's GEF function is required for growth factor-stimulated collagen 
synthesis and proliferation in HSCs. Together these results demonstrate that GIV and its 
GEF function is required for several key phenotypes that are critical for transdifferentiation 
and sustained activation of HSCs during progressive fibrosis.
PDGFRβ directly binds and phosphorylates GIV in activated HSCs
Next we asked which receptor(s) and ligands activate GIV-dependent signaling to potentiate 
HSC activation. First we analyzed signaling events triggered in Lx2 cells by PDGF and 
TGF-β1, the two major pro-fibrotic stimuli 2,3. We found that PDGF, but not TGFβ-1 
triggered phosphorylation of GIV at Tyr(Y)1764, a substrate site for RTKs 17 and 
Ser(S)1416, a substrate site for Akt 32, that are established surrogate markers of activation of 
the RTK-GIV-PI3K-Akt signaling pathway 17 (Figure 5A-B). However, both growth factors 
triggered phosphorylation of Akt, SMAD and ERK proteins (Figure 5A-B). Consistent with 
such activation, GIV co-immunoprecipitated with ligand-activated PDGFRβ (Figure 5C), 
along with Gαi and PI3K. Using recombinant proteins in pulldown assays we confirmed that 
the interaction between autophosphorylated PDGFRβ and GIV's C-terminus is direct 
(Figure 5D), and found that recombinant PDGFRβ phosphorylated GIV on tyrosines 1764 
and 1798 in vitro (Figure 5E); the same residues that are targeted by other RTKs 17. We 
found that tyrosine-phosphorylated GIV partially colocalized with activated PDGFRβ on 
patches at the PM in culture-activated primary HSCs (arrowheads, Figure 5F), as well as in 
PDGF-stimulated Lx2 cells (arrowheads, Figure 5G). These results demonstrate that upon 
PDGF stimulation, GIV and Gαi interact with activated PDGFRβ, presumably at the PM. 
Subsequent phosphorylation of GIV by PDGFR triggers the previously defined RTK(active)-
pTyrGIV-Gi-PI3K pathway 17. By contrast, neither GIV, nor Gαi could be detected in 
complex with TGFβR under the same conditions, suggesting that the Ser/Thr TGFβR kinase 
may not bind or directly transduce signal via GIV.
Next we investigated the temporal correlation between activation of the RTK(active)-
pTyrGIV-PI3K pathway (using phosphoTyr 1764 GIV as a surrogate marker) and collagen 
synthesis in culture-activated primary HSCs. On day 1, when collagen is still undetectable, 
pY1764-GIV is detected in ~50% of HSCs (Figure 5H, Supplementary Fig. 4). By day 3, 
~15-20% HSCs express collagen, whereas 100% express pY1764-GIV (Supplementary 
Fig. 4). Thus, early expression of GIV during HSC activation we observed before (Figure 
3A) is also accompanied by activation of the PDGFR-GIV-PI3K pathway, and both are 
upstream events that precede collagen synthesis during HSC activation. We confirmed that 
this pathway is activated in vivo during liver fibrosis because pY1764-GIV was detected 
exclusively in livers from BDL or CCl4-treated mice and not in control livers by IHC 
(Figure 5I). These results demonstrate that upon ligand stimulation, GIV directly binds 
autophosphorylated PDGFRβ, which allows: a) GIV to link G protein activation to RTK 
signaling, and b) phosphorylation of GIV by PDGFRβ; two events that synergistically 
enhance Akt signals via GIV 17.
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GIV enhances the pro-fibrotic PI3K-Akt and SMAD signals downstream of multiple 
receptors
Because the PI3K-Akt and TGFβ-SMAD pathways are major profibrotic signals that drive 
liver fibrosis 36 we asked if GIV and, more specifically, its GEF function or tyrosine 
phosphorylation modulates these signals in HSCs. To investigate this, we took advantage of 
two more previously validated GIV constructs: non-phosphorylatable Y1764/1798F mutant 
(GIV-YF), and GIV-FA/YF in which both GEF and tyrosines are mutated. We found that 
exogenous expression of GIV-WT, but not the mutants in Lx2 cells enhanced 
phosphorylation of both Akt and SMAD 2/3 proteins (Figure 6A), indicating that both 
GIV's GEF function and tyrosine phosphorylation are essential. Depletion of endogenous 
GIV in Lx2 cells suppressed Akt phosphorylation (Figure 6B); an effect reversed by 
exogenous expression of siRNA resistant GIV-WT, but not GIV-FA (Figure 6B), indicating 
that GIV's GEF function is required for maximal enhancement of Akt phosphorylation in 
HSCs. GIV's GEF function was also required for enhancement of Akt phosphorylation in 
response to a variety of ligands [serum, PDGF-BB, TGF-β1, RANTES, which activates G 
protein-coupled Chemokine receptors (CCRs), and lipopolysaccharide (LPS) which 
activates Toll-like receptors, TLR4] that target fibrogenic receptors of diverse classes 
(Figure 6C, 6D), indicating that GIV enhances the pro-fibrotic PI3K-Akt pathway 
downstream of multiple receptors via its GEF function. FoxO1, a major downstream target 
of Akt, whose inactivation and nuclear exclusion triggers HSCs transdifferentiation during 
liver fibrosis 10, was excluded from the nucleus in ~92% of the cells expressing GIV-WT 
(Figure 6E-F). By contrast, in cells expressing GIV-FA, FoxO1 was seen in the nucleus in 
~50% of the cells, indicating that GIV's GEF function is required for nuclear exclusion and 
inactivation of FoxO1. Furthermore, compared to cells expressing GIV-WT, those 
expressing GIV-FA displayed fewer stress fibers (Supplementary Fig. 5), an overall pro-
apoptotic phenotype [lower Bcl-2 (Figure 6G) and higher BAX (Figure 6H), higher 
Caspase 3 activity (Figure 6I) and more abundance of fragmented DNA analyzed by 
TUNEL (Figure 6J)], lower SMAD 2/3 activation, based on its decreased phosphorylation 
(Figure 6K), and reduced nuclear localization (Figure 6L-M). Taken together, these results 
demonstrate that GIV's GEF function is essential for key profibrogenic phenotypes that 
characterize HSC activation: actin cytoskeletal remodeling, HSCs survival, and enhanced 
PI3K-Akt-FoxO1 and the TGFβ-SMAD pathways.
GIV inhibits the anti-fibrotic cAMP signals downstream of multiple receptors
Next we asked if activation of Gαi via GIV's GEF function modulates anti-fibrotic cAMP 
signals during HSC activation. First, we confirmed that GIV expressed in HSCs bound G 
proteins as expected for a GEF 16,19, i.e., it preferentially bound inactive Gαi3 (GDP loaded) 
(Figure 7A), and not to Gαi3 in active conformation (loaded with GDP + AlF −4) in GST 
pulldown assays. Next we confirmed that various stimuli which require GIV's GEF function 
to enhance Akt (Figure 6D-E) can also trigger the activation of Gαi3 in Lx2 cells (Figure 
7B), as determined by an antibody that specifically recognizes the active GTP-bound 
conformation of Gαi 37. Depletion of endogenous GIV suppressed Gαi3 activity (Figure 
7C); an effect reversed by exogenous expression of siRNA resistant GIV-WT, but not GIV-
FA, indicating that GIV's GEF function is required for activation of Gαi3 in HSCs. As 
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expected, loss of Gαi3 activity in HSCs expressing GIV-FA, was accompanied by increased 
accumulation of cellular cAMP (Figure 7D), and enhanced phosphorylation (Figure 7E) 
and nuclear translocation (Figure 7F-G) of its downstream target, CREB, indicating that 
GIV's GEF function is required for inhibition of the cAMP-CREB pathway. These results 
demonstrate that GIV inhibits the anti-fibrogenic cAMP pathway in HSCs via its GEF 
function.
Taken together, we propose (Figure 8) that GIV serves as a central hub which integrates 
signals downstream of multiple fibrogenic receptors and simultaneously enhances the 
profibrotic (PI3-KAkt-FoxO1 and TGFβ-SMAD) and inhibits the anti-fibrotic (cAMP-PKA-
pCREB) pathways to shift the delicate balance between pro- and anti-fibrogenic signalling 
to an overall profibrotic signaling program that favors fibrosis. Consequently, phenotypes 
that are critical for sustained activation of HSCs and collagen synthesis are enhanced 
through a combination of transcriptional (via FoxO1, SMAD and CREB) and non-
transcriptional mechanisms (via PI3K, Akt and cytoskeletal remodeling).
Expression of GIV in liver biopsies correlates with the degree of fibrosis
Because GIV is upregulated early during liver fibrosis and its expression is required for 
HSC activation, we hypothesized that detection of GIV in liver biopsies could indicate 
sustained activation of HSCs and mark the potential for progression to cirrhosis. We tested 
this hypothesis in liver biopsies obtained from 21 males with chronic HCV infection because 
the rate of fibrogenic progression in these patients varies markedly, and the need for a 
biomarker that differentiates rapid from slow progressors still remains unmet 38. Fibrosis 
was staged with the Ishak scale (ranging from 0 = no fibrosis to 6 = cirrhosis) 38. As shown 
previously, GIV was undetectable in normal livers (Figure 9A, 9B-a) and detected in 100% 
of livers with moderate to severe fibrosis (scores 3-6) (Figure 9A and 9B-b). However, 
GIV was detected only in ~37% of livers with minimal or no fibrosis (scores = 0-2) (Figure 
9A and 9B-c, d). Noteworthy, GIV expression did not show any correlation with age, 
alcohol intake, degrees of inflammation, or fatty infiltration. These results demonstrate that 
some, but not all patients express GIV during the early stages of chronic viral hepatitis, even 
before significant fibrosis has occurred, but with the progression to cirrhosis, all are positive. 
Of the 8 patients with minimal or no fibrosis, 3 patients whose liver biopsies were positive 
for GIV progressed to advanced fibrosis, as determined by increasing FIB-4 (Figure 9C) 
and APRI (Figure 9D) scores 39,40 during a 3 year followup. These results suggest that GIV 
expression in liver biopsies may predict the progression of fibrosis, and thereby serve as a 
biomarker for the disease. We propose that detection of GIV in liver biopsies early during 
HCV infection might distinguish those who progress rapidly to cirrhosis from those who 
progress slowly or not at all.
Discussion
Here we define GIV as a central hub within the fibrogenic signaling network downstream of 
multiple receptors. By virtue of its ability to activate trimeric G protein Gi, GIV 
simultaneously modulates proand anti-fibrotic pathways that function antagonistically to 
balance collagen synthesis and its removal in a delicate equilibrium. Our results provide 
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detailed mechanistic insights into how GIV triggers HSC activation, and supports the model 
outlined in Figure 9E: In response to a variety of chronic injuries, diverse classes of 
fibrogenic receptors are activated, which triggers an upregulation of GIV mRNA, translation 
of GIV protein and its activation in HSCs. Increased expression and activation of GIV's 
GEF function enhances PI3K-Akt signaling downstream of numerous receptors and blunts 
cAMP accumulation, both via activation of Gαi. These upstream events trigger subsequent 
tiers of signals along the pro- and anti-fibrogenic pathways (see Figure 8), skewing the 
entire network towards an overall profibrotic signaling program that favors fibrogenesis. 
Consequently, several phenotypes (migration, proliferation, actin remodeling, survival/anti-
apoptosis and collagen production) that are critical not only for transdifferentiation of HSCs 
to an active state but also for a sustained increase in the abundance of activated HSCs in the 
liver during progressive liver injury, eventually leading to liver fibrosis. Depletion of GIV, 
or targeted inhibition of its GEF function reverses the profibrogenic program in HSCs, i.e., 
suppresses Akt activity and increases cellular cAMP, thereby 'resetting' the balance to an 
anti-fibrogenic program, as exists in normal liver. We conclude that GIV is a key transducer 
of signals downstream of multiple classes of fibrogenic receptors that trigger liver fibrosis.
Of the many receptors that utilize GIV to transduce profibrotic signals, we found that the 
fibrogenic RTK PDGFRβ directly binds and phosphorylates GIV. This is in keeping with 
our previous work on the prototype RTK, EGFR, in which we defined how GIV serves as a 
signaling platform that links ligand-activated RTKs to G protein signaling. Although the 
other major pro-fibrotic receptor i.e., TGFβR also requires GIV's GEF function to enhance 
Akt and SMAD signals and collagen synthesis, surprisingly, we could not identify a direct 
link (neither binding nor phosphoregulation) between them. Because TGFβ and PDGF 
pathways crosstalk 41-43, we hypothesize that GIV and its GEF function may enhance Akt 
signals in response to TGFβ indirectly via activation of PDGFR pathway. Similarly, because 
the PI3K-Akt pathway can potentiate fibrogenic SMAD signals in cells responding to 
TGFβ 44, it is possible that GIV and its GEF function enhance SMAD signals via activation 
of Akt.
We demonstrate that GPCRs, such as CCRs also require GIV's GEF function for 
enhancement of Akt activity when stimulated with RANTES. We previously demonstrated 
that GPCRs (e.g., LPAR1 and f-Met-Leu-Pro-R) require GIV and its GEF function for 
PI3K-Akt signaling and chemotaxis 16,19,45, and that they can trigger tyrosine 
phosphorylation and activation of GIV via activation of Src-family of non-RTKs 17. We 
conclude that CCRs modulate pro- and anti-fibrogenic signals via activation of GIV. Finally, 
we also provide evidence that TLR4, a receptor that is unique to fibrosis in the liver, also 
requires GIV's GEF function to enhance Akt signals when stimulated with LPS. Our 
findings are consistent with data showing that TLR4 requires activation of the PI3K-Akt 
pathway for enhancement of TGFβ-SMAD signaling 46,47, and that cirrhosis-predictive 
single nucleotide polymorphisms (SNPs) of TLR4 are functionally linked to genes of the 
PI3K-Akt pathway 48. We conclude that TLR4 activates Akt via GIV, and results shown 
here provide the first evidence for how GIV may shape the innate immune response by 
modulating signaling networks initiated by members of the Interleukin-1 (IL-1)/TLR 
superfamily. Because KCs are the main target of LPS in the liver 49, and these cells also 
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upregulated GIV mRNA after injury, it is possible that the TLR4-GIV-Akt pathway also 
helps to activate KCs during liver fibrosis.
Besides demonstrating that multiple fibrogenic receptors converge upon GIV, we 
demonstrate that subsequent activation of Gαi by GIV modulates two functionally 
antagonistic signaling events (see Figure 8)-- (a) Activation of the profibrotic PI3K-Akt 
signals that potentiate TGFβ-SMAD signals and inhibit FoxO1, and (b) inhibition of cAMP 
production, which suppresses the PKA-pCREB pathway; thereby generating an overall 
profibrotic signaling program that favors fibrosis. Because the PI3K-Akt pathway is strongly 
implicated in studies of fibrogenic diseases in other organ systems [skin, cardiac, pulmonary 
(reviewed in 50)], and the cAMP pathway is a well-accepted antifibrotic pathway in various 
other models of fibrogenesis (cardiac 51, pulmonary 42, kidney 44, and skin 26), and fibrosis 
in all organs share common receptors/pathways defined here (i.e., TGF-β1 and PDGF 52), 
we speculate that GIV may also serve as a key mediator in fibrogenic diseases of other 
organs.
The other important finding is the invariable upregulation of GIV mRNA and expression of 
GIV protein after several forms of chronic liver injury, in both humans and mice. Although 
here we focused on upregulation of GIV in HSCs, it is noteworthy that other cells like ECs 
and KCs which also contribute to liver fibrosis by promoting sustained activation of 
HSCs 53 showed significant upregulation of GIV after injury. This was not unexpected 
because GIV is known to be expressed in vascular endothelial cells15 and we previously 
showed that GIV is required for macrophage chemotaxis 19. As in the case of HSCs, 
activation and secretion of cytokines and chemokines by KCs is antagonistically balanced 
by the PI3K-Akt 7 and the cAMP-pCREB pathway 54. Because GIV modulates those two 
signaling pathways in HSCs, we suspect that GIV's role in liver fibrosis is not limited to 
activation of HSCs, but extends also to activation of KCs; all via common signal 
transduction mechanisms we outline here.
As for mechanism(s) of GIV upregulation, our results indicate that its expression may be 
regulated at multiple steps. For example, quiescent HSCs have low levels GIV mRNA but 
no protein is translated, indicating that protein translation is repressed or protein half-life is 
short in these cells. However, in activated HSCs, high levels of GIV mRNA and full-length 
protein are seen, indicating that transcriptional induction and/or RNA and/or protein 
stabilization are responsible for such upregulation. We have recently defined STAT3 as a 
key transcription factor responsible for upregulation of GIV in response to wounding and 
during cancer progression 22. Because STAT3 has been widely implicated in perpetuating 
inflammation/injury response in the liver 55, and liver fibrosis has been likened to would 
healing 23, it is possible that STAT3 up-regulates GIV after liver injury, thereby linking 
inflammation to fibrogenesis. Regardless of the mechanism(s) involved, we found that 
sustained upregulation of GIV is restricted to some forms of injuries, not others: 
upregulation occurs in all forms of chronic fibrogenic injuries, but not in acute injuries that 
heal without fibrosis. These results indicate that GIV is not merely a component of an acute 
phase response in the injured liver, instead, increased expression of GIV during acute 
injuries may signal a potential for progression to chronicity and fibrosis.
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With regard to the clinical relevance of our findings, we provide evidence that GIV could 
serve both as a therapeutic target against and a biomarker for prognosticating liver fibrosis. 
Our findings in HSCs expressing the GEF-deficient GIV-FA demonstrate that selective 
inhibition of the GIV:Gαi interface by a single point mutation is sufficient to alter a 
multitude of signals and inhibit various phenotypes that are required for sustained activation 
of HSCs. Based on these we conclude, that the GIV:Gαi interface is an effective and 
specific target, that is also sensitive to disruption. Furthermore, since accumulation of 
cellular cAMP can reverse fibrosis 13, and accumulation of cAMP is one of the direct 
consequences of inhibiting GIV's GEF function, we anticipate that antagonists targeting the 
GIV:Gαi interface will not only halt, but also cause regression of fibrosis by reinstating anti-
fibrotic signaling. Based on our findings that GIV's GEF function is utilized by multiple 
receptors, inhibiting the GIV:Gαi interface constitutes a novel strategy for externally 
manipulating multiple fibrogenic receptors via a single target. Because full-length GIV is 
not expressed in the normal liver, and the majority of cells in the liver (i.e., hepatocytes) do 
not express GIV even after injury, inhibition of GIV is likely to have fewer off-target effects 
on major metabolic functions of the liver. We conclude that small molecules against the 
GIV:Gαi interface have the potential of being both selective and broad-- i.e., selectively 
inhibit GIV-dependent profibrotic signaling in cells that express full-length GIV, yet broadly 
downstream of multiple receptors.
With regard to the prognostic potential of GIV, we provide proof-of-concept that detection 
of GIV in FFPE liver biopsies early during the course of chronic HCV infection (when 
significant fibrosis is yet to occur) may predict rapid progression to advanced fibrosis. Based 
on the fact that GIV expression in HSCs precedes collagen synthesis and onset of liver 
fibrosis, GIV fits the definition of an ideal prognosticator which identifies at-risk patients 
even at early stages when minimal or no fibrosis is detected by IHC. In addition, our IHC 
results show that full-length GIV is detected easily and reproducibly with 3 different CT 
antibodies, and that a simple binary system of scoring (i.e., presence or absence of GIV) is 
sufficient to distinguish at-risk individuals from others without the need for cumbersome 
and subjective scoring algorithms. Despite the potential significance of our findings, 
limitations of this and any future studies on this topic includes the frequent occurrence of 
sampling error in liver biopsies despite the fact that individual biopsies meet the histologic 
criteria for adequacy. To circumvent this limitation, here we used two different clinical 
scoring methods to monitor the progression of fibrosis, FIB-4 and APRI; each score is 
derived from multiple clinical parameters. We found that both scores concurrently classified 
the patients into two groups-- non-progressors (fibrosis stages F0 = no fibrosis; F1 = portal 
fibrosis without bridges; F2 = portal fibrosis with rare bridges) and progressors (fibrosis 
stages F3 = numerous bridges without cirrhosis; F4 = cirrhosis). Our results indicate that 
expression of GIV in HSCs by IHC was associated with progression of fibrosis to significant 
levels within 3 years. We conclude that GIV may serve as a prognostication biomarker for 
clinical use to identify those patients with chronic liver injury that are at highest risk for 
progressive fibrosis. Because growing evidence suggests that activated HSCs drive primary 
liver and biliary cancer progression 56, and because GIV is a bona fide prometastatic protein 
that imparts aggressiveness to multiple cancers 22,57, it is possible that levels of expression 
of GIV in HSCs correlates/predicts progression to liver cancer. Further studies on larger 
Lopez-Sanchez et al. Page 11
Nat Commun. Author manuscript; available in PMC 2015 January 21.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
cohorts of patients are required to evaluate if GIV expression in liver biopsies independently 
predicts liver cirrhosis and/or progression to cancer.
In conclusion, here we have defined GIV as a novel signaling hub at the center of the 
complex multi-receptor signaling system that drives liver fibrosis. Our findings set a new 
paradigm in which a single multidomain signal transducer centrally integrates and broadly 
shapes the entire fibrogenic network. As a promising therapeutic target which can serve as a 
biomarker to predict risk of fibrosis, GIV presents an opportunity for the practice of 
personalized medicine in patients with fibrogenic diseases of the liver.
Methods
Reagents and antibodies
Unless otherwise indicated, all reagents were of analytical grade and obtained from Sigma-
Aldrich. Cell culture media were purchased from Invitrogen. PDGF (Invitrogen), TGFβ1 
(Invitrogen), RANTES (R&D Systems), and LPS-E Coli 055:B5 (Sigma) were obtained 
commercially. BrdU was obtained from Sigma. Recombinant and PDGFRβ was purchased 
from Cell Signaling. All restriction endonucleases and Escherichia coli strain DH5α were 
purchased from New England Biolabs. E. coli strain BL21 (DE3), oligofectamine and 
phalloidin-Texas Red were purchased from Invitrogen. DAPI was purchased from 
Molecular Probes (Invitrogen). GenejuiceTM transfection reagent was obtained from 
Novagen (EMD Millipore) and PfuUltra DNA polymerase was purchased from Stratagene. 
Silencer Negative Control scrambled (Scr) siRNA was purchased from Ambion and and a 
previously validated 32 GIV siRNA sequence was custom-ordered from Dharmacon. Goat 
anti-rabbit and goat anti-mouse Alexa Fluor 680 or IRDye 800 F(ab')2 used for Odyssey 
Infrared Imaging were from Li-Cor Biosciences. Antibodies used in this work include rabbit 
pAbs against Gαi3 (M-14) and pan-Gβ (Santa Cruz Biotechnology), phospho-Akt Ser 473, 
phospho-ERK 1/2, phospho-SMAD 2 and phospho-CREB (Cell Signaling) and phospho-
Histone H3 (Abcam). Mouse mAbs against hexahistidine (His), FLAG (M2), actin and α-
tubulin (Sigma-Aldrich), SMAD 2/3, phospho-PDGFRβ-Tyr716 and GFP (Santa Cruz 
Biotechnology), BrdU (BD Biosciences), PDGFRβ (Biolegend), α-SMA (DAKO), control 
IgG (Bio-Rad Laboratories) and anti-active Caspase 3 (Abcam) were obtained 
commercially. Several anti-GIV antibodies were used in this work. For immunoblotting we 
used rabbit anti-GIV coiled-coil (GIVcc) (Millipore) and GIV-CT Abs (Santa Cruz 
Biotechnology). Coiled-coil antibody detects most isoforms of GIV, whereas CT Ab detects 
exclusively the full length isoform of GIV that contains the domains required for GIV's 
function as a signal transducer. For immunofluorescence we used rabbit monoclonal anti-
GIV-CT (Spring Bioscience) and anti-GIV-CT mAb (Millipore). Three different Anti-GIV-
CT Abs were used for IHC detection of GIV (Santa Cruz Biotechnology, IBL America and 
Spring Bioscience). All these CT antibodies were raised against the last 18 aa of the C-
terminus, and were validated in immunoblot assays based on their ability to specifically 
detect the full length GIV isoform. Anti-Tyr1764-GIV Ab was developed by Spring 
Bioscience using a proprietary platform for the generation of Rabbit mAb using a peptide 
encompassing pY1764. It is a diagnostic grade antibody jointly developed by our group, 
Ventana/Roche and Spring Biosciences and extensively validated in multiple assays prior to 
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use in this project. Anti-Ser1614-GIV was commercially obtained from IBL America, and 
was previously validated by the Takahashi group32. Anti-Gαi3:GTP (6-F12) was a gift from 
Dr. Graeme Milligan58.
Plasmid Constructs, Mutagenesis and Protein Expression
Cloning of Gαi3 into pGEX-4T-1 (GST-Gαi3), GIV-CT (aa 1,660-1,870) into pET28b (His-
GIV CT), and RNA interference-resistant (siRNA rest) GIV was generated by silent 
mutations32 and cloned into p3XFLAG-CMVTM-14 plasmid (GIV-FLAG) as described 
previously 16,19,26,45. His-PCT (Podocalyxin Tail) was a gift from Dr. Farquhar MG 59. GIV 
mutants were generated using QuickChange II (Stratagene) and specific primers (sequence 
available upon request) following the manufacturer's instructions. All constructs were 
checked by DNA sequencing.
GST, GST-Gαi3, His-GIV CT and His-PCT fusion constructs were expressed in E. coli 
strain BL21 (DE3) (Invitrogen) and purified as described previously 16,19,26. Bacterial 
cultures were induced overnight at 25°C with 1 mM isopropyl β-D-1-thiogalactopyranoside 
(IPTG). Pelleted bacteria from 1 L of culture were re-suspended in 10 ml GST-lysis buffer 
[25 mM Tris-HCl, pH 7.5, 20 mM NaCl, 1 mM EDTA, 20% (v:v) glycerol, 1% (v:v) Triton 
X-100, 2X protease inhibitor cocktail (Complete EDTA-free, Roche Diagnostics)] or His-
lysis buffer [50 mM NaH2PO4 pH 7.4, 300 mM NaCl, 10 mM imidazole, 1% (v:v) Triton 
X-100, 2X protease inhibitor cocktail (Complete EDTA-free, Roche Diagnostics)] for GST 
or His-fused proteins, respectively. After sonication (3 × 30s), lysates were centrifuged at 
12,000g at 4°C for 20 min. Solubilized proteins were affinity purified on glutathione-
Sepharose 4B beads (GE Healthcare) or HisPur Cobalt Resin (Pierce). Proteins were eluted, 
dialyzed overnight against PBS and stored at −80 °C.
Mice and fibrosis induction
Expression of collagen type I time was studied using reporter Col-GFP mice (pCol9GFP-
HS4,5 transgene) 30. For all other experiments 8- to 12-week-old male C57BL/6 mice 
(Jackson laboratories) underwent BDL surgery or administration of CCl4 exactly as 
described previously 7. Sham operation was performed similarly, except that the bile duct 
was not ligated. Animals were sacrificed 5 or 21 days after BDL. CCl4 (Sigma-Aldrich; 
diluted 1:3 in corn oil) or vehicle (corn oil) was administered via intraperitoneal route at a 
dose of 0.5 μl/g body weight, twice per week, for a total of 12 injections. Animals received 
humane care according to NIH recommendations outlined in the “Guide for the Care and 
Use of Laboratory Animals.” All animal experiments and cell isolation studies were 
approved by the UCSD Institutional Animal Care and Use Committees.
Isolation and Culture of Liver Cell Fractions from Mice
Liver cells of 8- to 12-week-old male C57BL/6 mice (Jackson laboratories) were 
fractionated into hepatocytes, Kupffer cells, endothelial cells and hepatic stellate cells as 
previously described 60. Perfusion of mouse livers was followed by 3-layer discontinuous 
density gradient centrifugation with 8.2% and 14.5% Nycodenz (Accurate Chemical and 
Scientific Corporation). Kupffer cell or endothelial cell fractions were then selected 
positively by magnetic cell sorting using anti-CD11b antibody or antiliver sinusoidal 
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endothelial cell antibody, respectively (Miltenyi Biotech). The hepatic stellate cell fraction 
was purified by negative selection for Kupffer cells and endothelial cells by magnetic cell 
sorting with respective antibodies. These cell fractions were homogenized immediately for 
RNA extraction. The purity of hepatocytes, HSCs and ECs were examined by phase-contrast 
microscopy, ultraviolet (UV)–excited autofluorescence (HSC), and uptake of diacetylated 
low-density lipoprotein (LDL) (EC). The purity of KC was demonstrated by functional 
analysis by means of phagocytosis of 1- μm latex beads. The purity of each cell type was as 
follows: hepatocytes, greater than 97%; EC, greater than 98%; KC, greater than 95%; HSC, 
greater than 96%. When we isolated HSCs for use in various assays throughout the 
manuscript, purity was confirmed as >98% by immunostaining with anti-desmin antibody. 
HSCs were cultured on uncoated plastic tissue culture dishes/coverslips in DMEM 
containing 10% FBS and used as primary cultures only.
RNA isolation and quantitative (qPCR)
Total RNA was isolated using an RNeasy kit (QIAGEN) as per the manufacturer's protocol. 
First-strand cDNA was synthesized using Superscript II reverse transcriptase (Invitrogen), 
followed by ribonuclease H treatment (Invitrogen) prior to performing quantitative real-time 
PCR. Reactions omitting reverse transcriptase were performed in each experiment as 
negative controls. Reactions were then run on a real-time PCR system (ABI StepOnePlus; 
Applied Biosystems). Gene expression was detected with SYBR green (Invitrogen), and 
relative gene expression was determined by normalizing to GAPDH using the ΔΔT method. 
Primers used in this work were designed targeting the last two exons of GIV such that they 
exclusively detect all known full length isoforms of GIV using Invitrogen's Oligo Perfec 
Designer and evaluated with NetPrimer from Premierbiosoft 26. The sequences of primers 
used in this work are included in Supplementary Table 1.
Patient samples
Human liver samples used for GIV mRNA analysis were collected at Mount Sinai Hospital. 
Cirrhosis samples were collected from HCV-infected patients undergoing surgical resection 
or liver transplantation for hepatocellular carcinoma. Normal liver tissue was collected from 
patients receiving hepatic resections for non-tumoral diseases, including hepatic adenoma 
and focal nodula hyperplasia. Liver samples were snap frozen, and RNA was extracted, 
DNase treated, reverse transcribed, and analyzed by quantitative real-time PCR as described 
above.
Liver biopsy specimens used in this work for IHC were obtained from 21 patients 
undergoing percutaneous liver biopsies from year 2009 to 2010 at the VA San Diego 
Healthcare System. Biopsies were performed using a standard Jamshidi aspiration needle 
and samples were formalin fixed immediately and embedded in paraffin. Adequacy of the 
biopsy specimen was established by the presence of at least 6-8 portal triads. In addition, 7 
specimens of normal liver were obtained from autopsies performed by the County of San 
Diego. All tissues used in this work were collected after IRB approval (Project# 04-0056 
0001 05 ME X and 101264) and with informed patient consent.
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As for limitations of this study, although the biopsies were done according to standard 
clinical practice and met current criteria for liver biopsy sampling, it is well known that 
sampling error can occur with liver biopsies despite meeting histologic criteria for individual 
biopsies. Despite the fact that sampling error is possible this remains the “gold standard” for 
determination of liver histology.
Immunohistochemistry
GIV IHC assays were developed and performed on a BenchMark XT automated slide stainer 
(Ventana Medical Systems, Inc.). FFPE samples (4 um section) were deparaffinized, 
pretreated for antigen retrieval, and followed by inactivation of endogenous peroxidase. 
Specimens were incubated with anti-GIV rabbit monoclonal (Ventana Medical Systems, 
Inc.) or polyclonal (IBL, Santa Cruz) antibodies (10 μg/ml) for 16 min at 37 C and the 
immunolocalized proteins were visualized using OptiView DAB IHC Detection kit. 
Following detection, all samples were counterstained with Hematoxylin II and Bluing 
Reagent. There was 100% concordance between all antibodies tested.
Semi-thin Immunofluorescence
Liver specimens were fixed with 4% paraformaldehyde for 4 h at 4°C, cryoprotected and 
frozen in liquid nitrogen. Semithin sections (0.5 μm) were cut with a Leica Ultracut UCT 
microtome equipped with a FCS cryoattachment at −100°C. Frozen sections were washed 
with PBS (3×), washed with 0.15% glycine (2×) and incubated 20 min in blocking buffer 
(5% normal goat serum, 2% fish skin gelatin and 2 mg/ml of BSA in PBS), 2 h in primary 
antibodies and 45 min in secondary antibodies. Dilutions of antibodies used were as follows: 
Mouse anti-GIV-CT (1:30), GFP (1:50); α-SMA (1:200); DAPI (1:1000) and secondary 
goat anti-mouse (594), goat anti-rabbit (488) and goat anti-rabbit (635) Alexa-conjugated 
antibodies (1:250). Sections were imaged on a Leica SPE confocal microscope using a 63x 
oil objective using 488, 561, 633 and 405 laser lines for excitation. The settings were 
optimized and the final images scanned with line-averaging of 3. All images were processed 
using Image J software (NIH) and assembled for presentation using Photoshop and 
Illustrator softwares (Adobe).
Whole-cell Immunofluorescence
Lx2 cells were fixed with 3% paraformaldehyde in PBS for 25 min at room temperature, 
treated with 0.1 M glycine for 10 min, and subsequently blocked/permeabilized with PBS 
containing 3% BSA and 0.2% Triton X-100 for 30 min at room temperature. Primary and 
secondary antibodies where incubated for 1 h at room temperature in PBS containing 3% 
BSA and 0.2% Triton X-100. Cells were imaged on a Leica SPE confocal microscope using 
a 63× oil objective using 488, 561 and 405 laser lines for excitation. The settings were 
optimized and the final images scanned with line-averaging of 3. Dilutions of antibodies 
used were as follows: GIVcc (1:150); GM130 (1:150); phospho-GIV (Tyr1764; 1:500); 
phospho-PDGFRβ (1:50); PDGFRβ (1:100); mouse anti-GIV-CT (1:100); Phalloidin 
(1:1000); DAPI (1:2000); secondary goat anti-rabbit (594) and goat anti-mouse (488) Alexa-
conjugated antibodies (1:500); anti-phospho-Histone H3 (Ser28) (1:150), anti-BrdU (1:10), 
SMAD 2/3 (1:100), phospho-CREB (1:250), FoxO1 (1:100) and anti-active Caspase 3 
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(1:200). All images were processed using Image J software (NIH) and assembled for 
presentation using Photoshop and Illustrator softwares (Adobe).
For assays investigating nuclear localization of transcription factors, % cells with nuclear 
localization was quantified by counting any nuclear staining as presence of transcription 
factor in the nucleus, and used that as a basis for a binary system (i.e., cells with or without 
nuclear localization of transcription factor). ~200-400 cells per condition were counted from 
three independent experiments.
Cell Culture, Transfection, Lysis, and Quantitative Immunoblotting
The Lx2 human hepatic stellate cell line was obtained from Scott Friedman (Mount Sinai, 
NY) and were cultured in DMEM media containing 2% FBS according to previously 
published guidelines 31. Transfection, lysis and immunoblotting were carried out exactly as 
described before 19,26,61.
Lx2 cells were transfected using Genejuice (Novagen) for DNA plasmids and 
Oligofectamine (Invitrogen) for siRNA oligos following the manufacturers’ protocols. For 
adenovirus infection, cells were incubated with the respective viruses at 50 MOI for 5 h. 
After, the medium was replaced and cells were maintained for 2-3 days. For assays 
involving serum starvation, serum concentration was reduced to 0% overnight and for serum 
reduced treatment 0.2% FBS was used. Whole-cell lysates were prepared after washing cells 
with cold PBS prior to resuspending and boiling them in sample buffer. Lysates used as a 
source of proteins in immunoprecipitation or pull-down assays were prepared by 
resuspending cells in lysis buffer [20 mM HEPES, pH 7.2, 5 mM Mg-acetate, 125 mM K-
acetate, 0.4% Triton X-100, 1 mM DTT, supplemented with sodium orthovanadate (500 
μM), phosphatase (Sigma) and protease (Roche) inhibitor cocktails], after which they were 
passed through a 28G needle at 4 °C, and cleared (10,000 × g for 10 min) before use in 
subsequent experiments.
For immunoblotting, protein samples were separated by SDS-PAGE and transferred to 
PVDF membranes (Millipore). Membranes were blocked with PBS supplemented with 5% 
nonfat milk (or with 5% BSA when probing for phosphorylated proteins) before incubation 
with primary antibodies. Infrared imaging with two-color detection and quantification were 
performed using a Li-Cor Odyssey imaging system. Dilution of primary antibodies were 
used as follows: Anti-His 1:1000; anti-FLAG 1:500; anti-GIV-CT 1:500; anti-phospho-GIV 
(Tyr1764) 1:500; anti-phospho-GIV (Ser1416) 1:500; anti-phospho-Akt 1:250; anti-Akt 
1:500; anti-phospho-ERK1/2 1:250; anti-Gαi3 1:333; anti-pan-Gβ 1:250; anti-α tubulin 
1:2000; anti-actin 1:1000; anti-SMAD2/3 1:250; anti-phospho-PDGFRβ 1:250; anti-
PDGFRβ 1:250 and anti-phospho CREB (1:1000). All Odyssey images were processed 
using Image J software (NIH) and assembled for presentation using Photoshop and 
Illustrator softwares (Adobe). Uncropped images of immunoblots are shown in 
Supplementary Fig. 7-9.
Cell Migration and Proliferation Assays
Lx2 cells were transfected with control scrambled (Scr) siRNA or GIV siRNA for ~36 h. 
Monolayer cultures (100% confluent) were then scratch-wounded using a 20 μl pipette tip, 
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and the cells were subsequently monitored by phase-contrast microscopy over the next 24 h. 
To quantify cell migration (expressed as percent of wound closure) images were analyzed 
using Image J software to calculate the difference between the wound area at 0 h and that at 
24 h divided by the area at 0 h × 100.
The proliferation rate of Lx2 cells was measured by phospho-Histone H3 (Ser28) (mitotic 
index) and BrdU incorporation (DNA replication in S phase) as previously described 20. For 
the mitotic index, cells were grown on coverslips for 24 h, then fixed and analyzed by 
confocal microscopy. For the BrdU uptake assay, Lx2 cells were grown on coverslips for 24 
h and treated with 10 μM BrdU for 30 min. Cells were then fixed with 70% ethanol for 30 
min at room temperature, washed with PBS (3×), treated with 2 M HCl for 20 min at room 
temperature, followed by 0.1 M Na2B407 (pH 8.5) for 2 min at room temperature. Finally, 
coverslips were washed with PBS (3×) and analyzed by confocal microscopy. For both 
phospho-Histone and BrdU assays 400-600 cells from 10 randomly chosen fields were 
counted (DAPI stained) from three independent experiments. Mitotic index was determined 
by dividing the number of positively stained cells/ the total number of DAPI-stained nuclei 
× 100. Results are shown as mean ± S.E.M of 10 fields from 3 separate experiments. For the 
mitotic index in primary murine HSCs, cells were isolated from mouse liver and grown on 
coverslips for 16 h. Then, mHSCs were infected with GIV-WT or GIV-FA adenoviruses and 
24 h later, cells were starved or treated with PDGF-BB (20 ng/ml 16 h) and mitotic index 
was measured by confocal microscopy.
Assays for measuring cellular apoptosis
Three different approaches were used. Lx2 cells were grown on coverslips and either 
transfected with control scrambled (Scr) siRNA or GIV siRNA for 48 h or infected with 
GIV-WT or GIV-FA adenoviruses and 24 h later, cells were starved for another 24 h. To 
measure Caspase 3 cleavage, cells were fixed and stained with anti-active Caspase 3 Ab 
(1:200). Measurement of DNA fragmentation by TUNEL assay was performed according to 
the protocol of In situ Cell Death Detection Kit, TMR red (Roche). 100 cells from randomly 
chosen fields were counted (DAPI stained) from three independent experiments. The percent 
of cells with either active Caspase 3 or fragmented DNA was determined by dividing the 
number of positively stained cells/ the total number of DAPI-stained nuclei × 100. 
Expression of two bona fide pro- (Bax) and anti- (Bcl-2) apoptotic signaling intermediates 
was measured by qPCR.
Generation of Adenoviruses Expressing GIV
HA-tagged full length human GIV wild-type (GIV-WT) and GIV-F1685A (GIV-FA) 
resistant to siRNA against human and murine GIV was cloned into pShuttle-CMV vector 62. 
The resultant plasmid was linearized with PacI and transformed into electrocompetent 
AdEasier E.coli (Agilent) using a Gene Pulser Electroporator (Bio-Rad). Correctly 
recombined clones were chosen based on sequencing and restriction endonuclease analyses, 
linearized with PacI and transfected into Cre8 cells (a gift from Dr. Ora Weisz, Univ. of 
Pittsburgh). Adenoviral particles were amplified using HEK-293 cells and purification was 
done using cesium chloride gradients 62.
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In vitro Pulldown Assays and Immunoprecipitation
Purified GST-Gαi3, GST alone, His-GIV CT or His-PCT were immobilized on either 
glutathione-Sepharose or HisPur Cobalt beads for 90 min at room temperature as described 
before 17,19,26,63. Lx2 HSCs lysates or phosphorylated PDGFRβ (50 ng) proteins were added 
to each tube, and binding reactions were carried out for 4 h at 4°C with constant tumbling in 
binding buffer [50 mM Tris-HCl (pH 7.4), 100 mM NaCl, 0.4% (v:v) Nonidet P-40, 10 mM 
MgCl2, 5 mM EDTA, 2 mM DTT, protease inhibitor mixture]. Beads were washed (4×) 
with 1 mL of wash buffer [4.3 mM Na2HPO4, 1.4 mM KH2PO4 (pH 7.4), 137 mM NaCl, 
2.7 mM KCl, 0.1% (v:v) Tween 20, 10 mM MgCl2, 5 mM EDTA, , 2 mM DTT] and boiled 
in Laemmli's sample buffer. When GST-Gαi3 was used in the assay, both binding buffer 
and washing buffer were supplemented with 30 μM GDP.
For immunoprecipitation, cell lysates (~2 mg of protein) were incubated for 4 h at 4°C with 
2 μg anti-PDGFR mAb or pre-immune control mouse IgG. Protein G Sepharose beads (GE 
Healthcare) were added and incubated at 4°C for an additional 60 min. Beads were washed 
and bound immune complexes were eluted by boiling in Laemmli's sample buffer.
For immunoprecipitation of active Gαi3, cell lysates were incubated for 1 h at 4°C with the 
conformational Gαi3: GTP mouse antibody (1 μg) 58 or pre-immune control mouse IgG. 
Protein G Sepharose beads (GE Healthcare) were added and incubated at 4°C for additional 
45 min. Beads were washed and immune complexes were eluted by boiling in Laemmli's 
sample buffer as previously described 59,61,62.
In vitro kinase assay
In vitro kinase assays were perfomed using purified His-GIV-CT or His-PCT proteins (~5 
μg) and commercially obtained PDGFRβ kinase (Cell Signaling). Reactions were started by 
addition of 1000 μM ATP and carried out at 25°C for 60 min in 30 μl kinase buffer [60 mM 
Hepes (pH 7.5), 5 mM MgCl2, 5 mM MnCl2, 3 μM Na3OV4]. Reactions were stopped by 
addition of Laemmli sample buffer and boiling.
Measurement of cAMP
Lx2 cells were transfected with GIV-WT or GIV-FA, serum starved (0% FBS, 16 h) and 
incubated with isobutylmethylxanthine (IBMX, 200 μM, 20 min) followed by PDGF (20 
ng/ml, 10 min) and Forskolin (10 μM, 10 min). Reactions were terminated by aspiration of 
media and addition of 150 μl of ice-cold TCA 7.5% (w/v). cAMP content in TCA extracts 
was determined by radioimmunoassay (RIA) and normalized to protein [(determined using a 
dyebinding protein assay (Bio-Rad)] 64. Data is expressed as fold change over Forskolin 
stimulation.
Data Analysis and Statistics
All experiments were repeated at least three times, and results were presented either as one 
representative experiment or as average ± S.D. Statistical significance was assessed with 
two-tailed Student's t test.
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Acknowledgements
We thank Marilyn Farquhar (UCSD) and Mikel Garcia-Marcos (Boston U) for helpful comments and critiques 
during the preparation of this manuscript, Katsumi Miyai (Pathology, UCSD) for generously giving us access to 
liver autopsy samples used in this work, Timo Meerloo for help with the preparation of semi-thin cryosections used 
to perform the immunofluorescence analysis, and Robert Esteban (Ventana Inc.) for optimization of IHC staining of 
liver sections. This work was supported by NIH grants CA160911 and DK099226, CAMS (Burroughs Wellcome 
Fund), and CSDA (Doris Duke Charitable Foundation) Awards to P.G. I.L-S was supported by American Heart 
Association (AHA #14POST20050025); Y.M. was supported by the Sarah Rogers Fellowship (UCSD). D.A.B was 
supported by P42ES010337, S.B.H. by Veterans Affairs Research Service, E.S by R01AA020172, R01DK085252 
and P42ES010337, and F.M. by NIH HL091061.
References
1. Friedman SL. Mechanisms of hepatic fibrogenesis. Gastroenterology. 2008; 134:1655–1669. 
[PubMed: 18471545] 
2. Pinzani M, Gesualdo L, Sabbah GM, Abboud HE. Effects of platelet-derived growth factor and 
other polypeptide mitogens on DNA synthesis and growth of cultured rat liver fat-storing cells. J 
Clin Invest. 1989; 84:1786–1793. doi:10.1172/JCI114363. [PubMed: 2592560] 
3. Gressner AM, Weiskirchen R, Breitkopf K, Dooley S. Roles of TGF-beta in hepatic fibrosis. 
Frontiers in bioscience : a journal and virtual library. 2002; 7:d793–807. [PubMed: 11897555] 
4. Svegliati-Baroni G, et al. Bile acids induce hepatic stellate cell proliferation via activation of the 
epidermal growth factor receptor. Gastroenterology. 2005; 128:1042–1055. [PubMed: 15825085] 
5. Yoshiji H, et al. Vascular endothelial growth factor and receptor interaction is a prerequisite for 
murine hepatic fibrogenesis. Gut. 2003; 52:1347–1354. [PubMed: 12912869] 
6. Svegliati-Baroni G, et al. Insulin and insulin-like growth factor-1 stimulate proliferation and type I 
collagen accumulation by human hepatic stellate cells: differential effects on signal transduction 
pathways. Hepatology (Baltimore, Md. 1999; 29:1743–1751.
7. Seki E, et al. CCR1 and CCR5 promote hepatic fibrosis in mice. J Clin Invest. 2009; 119:1858–
1870. [PubMed: 19603542] 
8. Chow EK, et al. TLR agonists regulate PDGF-B production and cell proliferation through TGF-
beta/type I IFN crosstalk. The EMBO journal. 2005; 24:4071–4081. doi:10.1038/sj.emboj.7600867. 
[PubMed: 16308570] 
9. Parsons CJ, Takashima M, Rippe RA. Molecular mechanisms of hepatic fibrogenesis. Journal of 
gastroenterology and hepatology. 2007; 22(Suppl 1):S79–84. [PubMed: 17567474] 
10. Adachi M, et al. The forkhead transcription factor FoxO1 regulates proliferation and 
transdifferentiation of hepatic stellate cells. Gastroenterology. 2007; 132:1434–1446. [PubMed: 
17408630] 
11. Son G, Hines IN, Lindquist J, Schrum LW, Rippe RA. Inhibition of phosphatidylinositol 3-kinase 
signaling in hepatic stellate cells blocks the progression of hepatic fibrosis. Hepatology 
(Baltimore, Md. 2009; 50:1512–1523. doi:10.1002/hep.23186. 
12. Solis-Herruzo JA, et al. G proteins are involved in the suppression of collagen alpha 1 (I) gene 
expression in cultured rat hepatic stellate cells. Cellular signalling. 1998; 10:173–183. [PubMed: 
9607140] 
13. Liu X, Sun SQ, Hassid A, Ostrom RS. cAMP inhibits transforming growth factor-beta-stimulated 
collagen synthesis via inhibition of extracellular signal-regulated kinase 1/2 and Smad signaling in 
cardiac fibroblasts. Molecular pharmacology. 2006; 70:1992–2003. [PubMed: 16959941] 
14. Ghosh AK, Yuan W, Mori Y, Varga J. Smad-dependent stimulation of type I collagen gene 
expression in human skin fibroblasts by TGF-beta involves functional cooperation with p300/CBP 
transcriptional coactivators. Oncogene. 2000; 19:3546–3555. doi:10.1038/sj.onc.1203693. 
[PubMed: 10918613] 
Lopez-Sanchez et al. Page 19
Nat Commun. Author manuscript; available in PMC 2015 January 21.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
15. Kitamura T, et al. Regulation of VEGF-mediated angiogenesis by the Akt/PKB substrate Girdin. 
Nature cell biology. 2008; 10:329–337. [PubMed: 18264090] 
16. Garcia-Marcos M, Ghosh P, Farquhar MG. GIV is a nonreceptor GEF for G alpha i with a unique 
motif that regulates Akt signaling. Proceedings of the National Academy of Sciences of the United 
States of America. 2009; 106:3178–3183. doi:10.1073/pnas.0900294106. [PubMed: 19211784] 
17. Lin C, et al. Tyrosine phosphorylation of the Galpha-interacting protein GIV promotes activation 
of phosphoinositide 3-kinase during cell migration. Sci Signal. 2011; 4:ra64. doi:10.1126/
scisignal.2002049. [PubMed: 21954290] 
18. Jiang P, et al. An actin-binding protein Girdin regulates the motility of breast cancer cells. Cancer 
research. 2008; 68:1310–1318. [PubMed: 18316593] 
19. Ghosh P, Garcia-Marcos M, Bornheimer SJ, Farquhar MG. Activation of Galphai3 triggers cell 
migration via regulation of GIV. The Journal of cell biology. 2008; 182:381–393. doi:10.1083/jcb.
200712066. [PubMed: 18663145] 
20. Lopez-Sanchez I, et al. Protein kinase C-theta (PKCtheta) phosphorylates and inhibits the guanine 
exchange factor, GIV/Girdin. Proceedings of the National Academy of Sciences of the United 
States of America. 2013; 110:5510–5515. doi:10.1073/pnas.1303392110. [PubMed: 23509302] 
21. Ghosh P, Garcia-Marcos M, Farquhar MG. GIV/Girdin is a rheostat that fine-tunes growth factor 
signals during tumor progression. Cell adhesion & migration. 2011; 5:237–248. [PubMed: 
21546796] 
22. Dunkel Y, et al. STAT3 protein up-regulates Galpha-interacting vesicle-associated protein (GIV)/
Girdin expression, and GIV enhances STAT3 activation in a positive feedback loop during wound 
healing and tumor invasion/metastasis. The Journal of biological chemistry. 2012; 287:41667–
41683. doi:10.1074/jbc.M112.390781. [PubMed: 23066027] 
23. Albanis E, Friedman SL. Hepatic fibrosis. Pathogenesis and principles of therapy. Clinics in liver 
disease. 2001; 5:315–334. v–vi. [PubMed: 11385966] 
24. Schuppan D, Krebs A, Bauer M, Hahn EG. Hepatitis C and liver fibrosis. Cell death and 
differentiation. 2003; 10(Suppl 1):S59–67. doi:10.1038/sj.cdd.4401163. [PubMed: 12655347] 
25. Weiler-Normann C, Herkel J, Lohse AW. Mouse models of liver fibrosis. Zeitschrift fur 
Gastroenterologie. 2007; 45:43–50. doi:10.1055/s-2006-927387. [PubMed: 17236120] 
26. Ghosh P, et al. A G{alpha}i-GIV molecular complex binds epidermal growth factor receptor and 
determines whether cells migrate or proliferate. Molecular biology of the cell. 2010; 21:2338–
2354. doi:10.1091/mbc.E10-01-0028. [PubMed: 20462955] 
27. Wu, J.; Kuncio, GS.; Zern, MA. Liver Growth and Repair. Strain, Alastair; Mae Diehl, Anne, 
editors. Springer Netherlands; 1998. p. 558-576.
28. Moreira RK. Hepatic stellate cells and liver fibrosis. Archives of pathology & laboratory medicine. 
2007; 131:1728–1734. doi:10.1043/1543-2165(2007)131[1728:HSCALF]2.0.CO;2. [PubMed: 
17979495] 
29. Mederacke I, et al. Fate tracing reveals hepatic stellate cells as dominant contributors to liver 
fibrosis independent of its aetiology. Nature communications. 2013; 4:2823. doi:10.1038/
ncomms3823. 
30. Yata Y, et al. DNase I-hypersensitive sites enhance alpha1(I) collagen gene expression in hepatic 
stellate cells. Hepatology (Baltimore, Md. 2003; 37:267–276. doi:10.1053/jhep.2003.50067. 
31. Xu L, et al. Human hepatic stellate cell lines, LX-1 and LX-2: new tools for analysis of hepatic 
fibrosis. Gut. 2005; 54:142–151. doi:10.1136/gut.2004.042127. [PubMed: 15591520] 
32. Enomoto A, et al. Akt/PKB regulates actin organization and cell motility via Girdin/APE. 
Developmental cell. 2005; 9:389–402. [PubMed: 16139227] 
33. Basu A, Haldar S. The relationship between BcI2, Bax and p53: consequences for cell cycle 
progression and cell death. Molecular human reproduction. 1998; 4:1099–1109. [PubMed: 
9872359] 
34. Wright MC, et al. Gliotoxin stimulates the apoptosis of human and rat hepatic stellate cells and 
enhances the resolution of liver fibrosis in rats. Gastroenterology. 2001; 121:685–698. [PubMed: 
11522753] 
35. Elmore S. Apoptosis: a review of programmed cell death. Toxicologic pathology. 2007; 35:495–
516. doi:10.1080/01926230701320337. [PubMed: 17562483] 
Lopez-Sanchez et al. Page 20
Nat Commun. Author manuscript; available in PMC 2015 January 21.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
36. Cong M, Iwaisako K, Jiang C, Kisseleva T. Cell signals influencing hepatic fibrosis. International 
journal of hepatology. 2012; 2012:158547. doi:10.1155/2012/158547. [PubMed: 22973518] 
37. Lane JR, Powney B, Wise A, Rees S, Milligan G. G protein coupling and ligand selectivity of the 
D2L and D3 dopamine receptors. The Journal of pharmacology and experimental therapeutics. 
2008; 325:319–330. doi:10.1124/jpet.107.134296. [PubMed: 18218829] 
38. Chen SL, Morgan TR. The natural history of hepatitis C virus (HCV) infection. International 
journal of medical sciences. 2006; 3:47–52. [PubMed: 16614742] 
39. Vallet-Pichard A, et al. FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection. 
comparison with liver biopsy and fibrotest. Hepatology (Baltimore, Md. 2007; 46:32–36. doi:
10.1002/hep.21669. 
40. Chou R, Wasson N. Blood tests to diagnose fibrosis or cirrhosis in patients with chronic hepatitis C 
virus infection. Annals of internal medicine. 2013; 159:372. doi:
10.7326/0003-4819-159-5-201309030-00021. [PubMed: 24026329] 
41. Shah R, et al. TGF-beta1 Up-Regulates the Expression of PDGF-beta Receptor mRNA and 
Induces a Delayed PI3K-, AKT-, and p70 -Dependent Proliferative Response in Activated Hepatic 
Stellate Cells. Alcoholism, clinical and experimental research. 2013 doi:10.1111/acer.12167. 
42. Messadi DV, et al. Effect of TGF-beta 1 on PDGF receptors expression in human scar fibroblasts. 
Frontiers in bioscience : a journal and virtual library. 1998; 3:a16–22. [PubMed: 9450987] 
43. Ikuno Y, Kazlauskas A. TGFbeta1-dependent contraction of fibroblasts is mediated by the 
PDGFalpha receptor. Investigative ophthalmology & visual science. 2002; 43:41–46. [PubMed: 
11773010] 
44. Das F, et al. Akt kinase targets association of CBP with SMAD 3 to regulate TGFbeta-induced 
expression of plasminogen activator inhibitor-1. Journal of cellular physiology. 2008; 214:513–
527. doi:10.1002/jcp.21236. [PubMed: 17671970] 
45. Garcia-Marcos M, Ghosh P, Ear J, Farquhar MG. A structural determinant that renders G alpha(i) 
sensitive to activation by GIV/girdin is required to promote cell migration. The Journal of 
biological chemistry. 2010; 285:12765–12777. doi:10.1074/jbc.M109.045161. [PubMed: 
20157114] 
46. Jia Y, Turek JJ. Altered NF-kappaB gene expression and collagen formation induced by 
polyunsaturated fatty acids. The Journal of nutritional biochemistry. 2005; 16:500–506. [PubMed: 
16043032] 
47. He Z, Zhu Y, Jiang H. Toll-like receptor 4 mediates lipopolysaccharide-induced collagen secretion 
by phosphoinositide3-kinase-Akt pathway in fibroblasts during acute lung injury. Journal of 
receptor and signal transduction research. 2009; 29:119–125. [PubMed: 19519177] 
48. Guo J, et al. Functional linkage of cirrhosis-predictive single nucleotide polymorphisms of Toll-
like receptor 4 to hepatic stellate cell responses. Hepatology (Baltimore, Md. 2009; 49:960–968.
49. Schwabe RF, Seki E, Brenner DA. Toll-like receptor signaling in the liver. Gastroenterology. 
2006; 130:1886–1900. doi:10.1053/j.gastro.2006.01.038. [PubMed: 16697751] 
50. Kisseleva T, Brenner DA. Mechanisms of fibrogenesis. Exp Biol Med (Maywood). 2008; 
233:109–122. doi:10.3181/0707-MR-190. [PubMed: 18222966] 
51. Swaney JS, et al. Inhibition of cardiac myofibroblast formation and collagen synthesis by 
activation and overexpression of adenylyl cyclase. Proceedings of the National Academy of 
Sciences of the United States of America. 2005; 102:437–442. [PubMed: 15625103] 
52. Kisseleva T, Brenner DA. Fibrogenesis of parenchymal organs. Proceedings of the American 
Thoracic Society. 2008; 5:338–342. doi:10.1513/pats.200711-168DR. [PubMed: 18403330] 
53. Kolios G, Valatas V, Kouroumalis E. Role of Kupffer cells in the pathogenesis of liver disease. 
World journal of gastroenterology : WJG. 2006; 12:7413–7420. [PubMed: 17167827] 
54. Chao W, Liu HL, Zhou WG, Hanahan DJ, Olson MS. Regulation of platelet-activating factor 
receptor and platelet-activating factor receptor-mediated biological responses by cAMP in rat 
Kupffer cells. The Journal of biological chemistry. 1990; 265:17576–17583. [PubMed: 2170386] 
55. Wang H, Lafdil F, Kong X, Gao B. Signal transducer and activator of transcription 3 in liver 
diseases: a novel therapeutic target. International journal of biological sciences. 2011; 7:536–550. 
[PubMed: 21552420] 
Lopez-Sanchez et al. Page 21
Nat Commun. Author manuscript; available in PMC 2015 January 21.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
56. Coulouarn C, et al. Hepatocyte-stellate cell cross-talk in the liver engenders a permissive 
inflammatory microenvironment that drives progression in hepatocellular carcinoma. Cancer 
research. 2012; 72:2533–2542. doi:10.1158/0008-5472.CAN-11-3317. [PubMed: 22419664] 
57. Garcia-Marcos M, et al. Expression of GIV/Girdin, a metastasis-related protein, predicts patient 
survival in colon cancer. Faseb J. 2011; 25:590–599. doi:10.1096/fj.10-167304. [PubMed: 
20974669] 
58. Lane JR, et al. Antibodies that identify only the active conformation of G(i) family G protein alpha 
subunits. Faseb J. 2008; 22:1924–1932. doi:10.1096/fj.07-100388. [PubMed: 18199696] 
59. Fukasawa H, et al. Phosphorylation of podocalyxin (Ser415) Prevents RhoA and ezrin activation 
and disrupts its interaction with the actin cytoskeleton. The American journal of pathology. 2011; 
179:2254–2265. doi:10.1016/j.ajpath.2011.07.046. [PubMed: 21945805] 
60. Taura K, et al. Hepatic stellate cells secrete angiopoietin 1 that induces angiogenesis in liver 
fibrosis. Gastroenterology. 2008; 135:1729–1738. doi:10.1053/j.gastro.2008.07.065. [PubMed: 
18823985] 
61. Garcia-Marcos M, Ear J, Farquhar MG, Ghosh P. A GDI (AGS3) and a GEF (GIV) regulate 
autophagy by balancing G protein activity and growth factor signals. Molecular biology of the cell. 
2011; 22:673–686. doi:10.1091/mbc.E10-08-0738. [PubMed: 21209316] 
62. Luo J, et al. A protocol for rapid generation of recombinant adenoviruses using the AdEasy system. 
Nature protocols. 2007; 2:1236–1247. doi:10.1038/nprot.2007.135. [PubMed: 17546019] 
63. Garcia-Marcos M, et al. Functional characterization of the guanine nucleotide exchange factor 
(GEF) motif of GIV protein reveals a threshold effect in signaling. Proceedings of the National 
Academy of Sciences of the United States of America. 2012; 109:1961–1966. doi:10.1073/pnas.
1120538109. [PubMed: 22308453] 
64. Ostrom RS, et al. Receptor number and caveolar co-localization determine receptor coupling 
efficiency to adenylyl cyclase. The Journal of biological chemistry. 2001; 276:42063–42069. doi:
10.1074/jbc.M105348200. [PubMed: 11533056] 
Lopez-Sanchez et al. Page 22
Nat Commun. Author manuscript; available in PMC 2015 January 21.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Figure 1. Expression of GIV increases in liver after chronic fibrogenic injury
(A) GIV mRNA levels were analyzed in livers from normal and HCV-infected patients with 
variable degrees of fibrosis by semi-quantitative (top) and quantitative PCR (bottom). 
Representative results for semi-quantitative PCR and a scattergram showing the fold 
induction of GIV mRNA are shown. Horizontal bar = mean. n = number of animals.
(B, C) GIV mRNA levels were analyzed in livers of mice subjected to BDL or sham surgery 
(B), or chronic injections of CCl4 or vehicle control (C) by qPCR as in A. Results are shown 
as fold change compared with sham- and vehicle-treated controls. . Error bars represent 
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mean ± S.D. n = number of animals. Statistical significance was assessed with two-tailed 
Student's t test.
(D, E) Total liver lysates from mice subjected to BDL or sham surgery (D) chronic 
injections of CCl4 or vehicle control (E) were analyzed for full-length GIV, phospho-Akt 
(pAkt), and total Akt (tAkt) by immunoblotting (IB).
(F) FFPE liver sections from mice subjected to BDL or CCl4 injury and their respective 
controls were analyzed for expression of full-length GIV protein (CT-Ab) by IHC. Boxed 
area in top panel is magnified in bottom panels. Magnification = 10X.
(G) FFPE liver sections from normal subjects or from patients with a variety of chronic liver 
injuries were analyzed for GIV as in E. Images are representative of 4-11 livers analyzed in 
each category. Boxed area in top panel is magnified in bottom panels. Magnification = 10X.
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Figure 2. Expression of full-length GIV mRNA and protein increases in HSCs after injury
(A) Isolated cell fractions from livers of mice subjected to BDL or sham surgery were 
analyzed for GIV and GAPDH mRNA levels by RT-PCR.
(B, C) Primary HSCs isolated from livers of mice subjected to BDL or sham surgery (B) or 
injections of CCl4 or vehicle control (C) were analyzed for GIV mRNA by qPCR. Results 
are shown as fold change compared with sham- and vehicle-treated controls, respectively. 
Error bars represent mean ± S.D. n = number of animals. Statistical significance was 
assessed with two-tailed Student's t test.
(D) Semi-thin liver sections from Col-GFP mice chronically treated with injections of CCl4 
or vehicle control were stained for GIV (red), Collagen (GFP, green), α-SMA (purple) and 
DAPI/DNA (blue) and analyzed by confocal microscopy. Arrowheads = α-SMA pos, Col 
pos, GIV pos (i.e., HSCs); Stars = α-SMA neg, GIV pos, likely to be KCs and Sinusoidal 
ECs. Scale bar = 10 μm.
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Figure 3. Expression of GIV mRNA and protein precedes activation and collagen production in 
culture-activated HSCs
(A) Primary HSCs isolated from livers of Col-GFP mice were culture-activated on uncoated 
plastic dishes for 7 days. Cells were fixed at various time points and stained for GIV (red) 
and DAPI/DNA (blue). Collagen production was detected by GFP signal as a surrogate 
marker. Representative images on different days are shown. Scale bar = 10 μm.
(B-E) Primary HSCs isolated from livers of Col-GFP mice were culture-activated on 
uncoated plastic dishes for 7 days. GIV (B), collagen (C) and α-SMA (D) mRNA levels 
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were measured by qPCR at different time points. (E) Expression patterns of GIV, collagen 
and α-SMA in B-D are plotted as line graphs superimposed on each other. GIV expression 
precedes peak expression of α-SMA and collagen. Results are shown as fold change 
compared with day 0 for each target transcript.
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Figure 4. GIV is required for actin remodeling, proliferation, migration, survival and collagen 
production in HSCs
(A) Lx2 cells were treated either with control (Scr) or with G cvcIV siRNA, lysates were 
analyzed for GIV depletion by immunoblotting (IB).
(B) Control (Scr) and GIV siRNA-treated Lx2 cells were fixed and stained for Phalloidin 
(red) and DAPI/DNA (blue), and visualized by confocal microscopy. Scale bar = 20 μm.
(C) Control (Scr) or GIV siRNA-treated Lx2 cells were analyzed for their ability to migrate 
and close a scratch-wound by serial imaging of the wound area (see Supplementary Fig. 
3B). Results are expressed as % wound closure.
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(D, E) Lx2 cells as in C were analyzed for nuclear phospho-Histone H3 or BrDU uptake by 
immunofluorescence and analyzed by confocal microscopy (see Supplementary Fig. 3C, 
D). Results are expressed as % cells positive for staining.
(F, G) Control (Scr) or GIV siRNA-treated Lx2 cells were analyzed for BAX (F) and Bcl-2 
(G) mRNA by qPCR. Results are displayed as fold change compared to their respective Scr-
treated controls.
(H, I) Control (Scr) or GIV siRNA-treated Lx2 cells were analyzed for cleaved Caspase 3 
(I) by immunofluorescence and fragmented DNA by TUNEL staining (H). Bar graphs 
display % cells with cleaved Caspase 3 (I) or fragmented DNA (H; TUNEL) on Y axis.
(J) Lx2 cells were treated with control (Scr) or GIV siRNA or transfected with siRNA-
resistant GIV-WT or GIV-FA, as indicated, starved and subsequently treated with TGF-β1. 
Collagen α1 mRNA was determined by qPCR and results are displayed as fold change 
compared to starved controls (Y axis).
(K, L) Primary murine HSCs were infected with adenoviruses expressing HA-tagged GIV-
WT or GIV-FA, starved, and subsequently treated with TGF-β1 (I) or PDGF-BB (J). 
Collagen α1 mRNA level was determined by qPCR. Results are displayed as fold change 
compared to starved controls (Y axis) (I) and mitotic index was analyzed using phospho-
Histone H3 (J) as in D. Results are displayed as % of cells positive for nuclear phospho-
Histone H3 (Y axis). Error bars represent mean ± S.D. n = 3. Statistical significance was 
assessed with two-tailed Student's t test.
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Figure 5. PDGFRβ directly binds and phosphorylates GIV in HSCs during liver injury
(A, B) Whole cell lysates of Lx2 cells stimulated with either PDGF-BB (A) or with TGF-β1 
(B) were analyzed for various signaling pathways by immunoblotting (IB).
(C) Immunoprecipitation was carried out on lysates (right panel) of serum-starved or PDGF-
BB treated Lx2 cells with anti-PDGFR or control IgG. Bound immune complexes (left) 
were analyzed for GIV, total (t) and activated (pY716) PDGFR, p85α(PI3K) and Gαi3 by 
immunoblotting (IB). M = Mix of starved and stimulated Lx2 lysates.
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(D) GST-PDGFR was autophosphorylated in vitro and used in pull-down assays with 
purified His-GIV CT or His-PCT (Podocalyxin Tail; a negative control). Bound receptor 
was visualized by immunoblotting (IB) using phospho-Tyr (pTyr) antibody. Equal amounts 
of His-tagged ligands were confirmed by Ponceau S stain.
(E) In vitro kinase assays were carried out with recombinant PDGFR on wild-type (WT) and 
phosphomutants of His-GIV CT. Reactions were analyzed for pTyr and His-GIV-CT by 
immunoblotting (IB). Yellow pixels in the merged panel (pTyr and His) shows 
phosphoGIV-CT.
(F) Culture-activated primary HSCs from Col-GFP mice were fixed and stained for active 
pY1764GIV (red) and active pY716PDGFR (cyan). Merge panel shows colocalization of 
red and cyan pixels at the PM (arrowheads). Arrowheads = Plasma membrane. Scale bar = 
25 μm.
(G) Lx2 cells stimulated with PDGF-BB were fixed and stained for pY1764GIV (red), 
active pY716PDGFR (green) and DAPI/DNA (blue). Merge panel shows yellow pixels 
indicative of colocalization at the PM (arrowheads). Arrowheads = Plasma membrane. Scale 
bar = 10 μm.
(H) Culture-activated primary HSCs were fixed and stained for active pY1764GIV (red) and 
DAPI/DNA (blue). Collagen production was detected by GFP signal. Scale bar = 10 μm. F, 
G and H were analyzed by confocal microscopy.
(I) Left: Liver sections from mice subjected to BDL or CCl4 injury were analyzed for active 
pY1764GIV by IHC. Boxed area on left panels are magnified on the right. Right: No 
staining was observed in the respective controls for both experimental models. 
Magnification = 10X.
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Figure 6. GIV's GEF function enhances profibrogenic Akt and SMAD signals in HSCs
(A) Whole cell lysates of Lx2 cells expressing GIV mutants were analyzed for various 
signaling pathways by immunoblotting (IB).
(B-D) Lx2 cells treated with control (Scr) or GIV siRNA were transfected with siRNA 
resistant GIV-WT or the indicated mutants, starved (0% FBS), and then stimulated with 
serum or various ligands prior to lysis. Equal aliquots of lysates were analyzed for GIV, 
phospho- and total Akt by immunoblotting (IB).
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(E-F) Lx2 cells infected with GIV-WT-HA or GIV-FA-HA adenoviruses were maintained 
in 0.2% FBS, fixed and stained for HA (GIV, green), FoxO1 (red) and DAPI/DNA (blue) 
and analyzed by confocal microscopy. Star = nuclear FoxO1. Scale bar = 10 μm. Results 
display % cells with nuclear FoxO1 (Y axis) (F).
(G, H) Lx2 cells depleted of endogenous GIV were subsequently transfected with various 
GIV constructs, and RNA extracted of these cells were analyzed for Bcl-2 (G) and BAX (H) 
mRNA levels by qPCR.
(I, J) Lx2 cells were infected with GIV-WT-HA or GIV-FA-HA adenoviruses, maintained 
in 0 % FBS, fixed and analyzed for cleaved Caspase 3 (J) by immunofluorescence and for 
fragmented DNA by TUNEL staining (I). Bar graphs display % cells with cleaved Caspase 
3 (J) or fragmented DNA (I; TUNEL) on Y axis.
(K) Lx2 cells depleted of endogenous GIV were subsequently transfected with siRNA-
resistant GIV-WT or GIV-FA, stimulated with TGFβ and phospho- (p)SMAD and total 
(t)SMAD 2/3 were analyzed by immunoblotting (IB). The ratio of pSMAD/tSMAD was 
~2.0 fold higher in cells expressing GIV-WT than in those expressing GIV-FA, as 
determined by band densitometry.
(L, M) Lx2 cells infected with GIV-WT-HA or GIV-FA-HA adenoviruses were maintained 
in 0.2% FBS, fixed and stained for HA (GIV, green), SMAD2/3 (red) and DAPI/DNA 
(blue) and analyzed by confocal microscopy. Star = nuclear SMAD2/3. Scale bar = 10 μm. 
(M) Bar graphs display % cells with nuclear tSMAD2/3 in K. Error bars represent mean ± 
S.D. n = 3. Statistical significance was assessed with two-tailed Student's t test.
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Figure 7. GIV activates Gαi and suppresses the anti-fibrogenic cAMP/PKA/pCREB signals in 
HSCs
(A) Lysates of Lx2 cells were used as the source of full-length GIV in pull-down assays 
with GST or GST-Gαi3 preloaded with GDP alone (inactive) or with AlF −4 (active), and 
immobilized on glutathione beads. Bound GIV and Gβγ were analyzed by immunoblotting 
(IB). The GST proteins are shown by Ponceau S stain.
(B) Serum-starved Lx2 cells were stimulated with a variety of ligands prior to lysis. Equal 
aliquots of lysates were subjected to immunoprecipitation with Gαi:GTP mAb, which 
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recognizes active conformation of the G protein and immunecomplexes were analyzed for 
Gαi3 by immunoblotting (IB).
(C) Lx2 cells treated with control (Scr) or GIV siRNA were transfected with siRNA 
resistant GIV-WT or GIV-FA and maintained in 0.2% FBS. Lysates were analyzed for 
active Gαi3 as in B.
(D) Lx2 cells transfected with GIV-WT or GIV-FA were stimulated with PDGF-BB prior to 
lysis. Lysates were analyzed for cAMP by RIA and normalized to total protein. Results are 
displayed as fold change in cAMP (Y axis).
(E) Lx2 cells transfected with GIV-WT or GIV-FA were analyzed for GIV, phospho(p)Akt, 
phospho(p)CREB and tubulin by immunoblotting (IB). The ratio of pCREB/tubulin was 
~2.5 fold higher in cells expressing GIV-FA than in those expressing GIV-WT, as 
determined by band densitometry.
(F) Lx2 cells infected with GIV-WT-HA or GIV-FA-HA adenoviruses were maintained in 
0.2% FBS, fixed and stained for HA (GIV, green), phospho(p)CREB (red) and DAPI/DNA 
(blue) and analyzed by confocal microscopy. Arrowhead = GIV expressing cell. Star = 
nuclear p CREB. Scale bar = 10 μm. Results display % cells with nuclear pCREB (Y axis) 
(G). Error bars represent mean ± S.D. n = 3. Statistical significance was assessed with two-
tailed Student's t test.
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Figure 8. GIV enhances pro-fibrogenic and inhibits anti-fibrogenic signaling pathways in HSCs
Ligand stimulation of diverse classes of fibrogenic receptors (top) converge upon GIV either 
via direct interaction (solid arrow) or via unknown mechanism (interrupted arrow) to 
enhance PI3K-Akt signaling (1) and activate trimeric Gαi (2). GIV-dependent activation of 
Akt elicits several non-transcriptional responses (3) that lead into activation of HSCs. The 
GIV-PI3K-Akt pathway also modulates two distinct transcriptional programs-- (i) 
Potentiation of the profibrotic TGFβ-SMAD pathway by increasing phosphorylation of 
SMAD2/3 (4) and its translocation into the nucleus (5), and thereby, enhancing proliferation 
and transcription of collagen and α-SMA (6); (ii) Inhibition of the transcription factor Foxo1 
by phosphorylation (7) and by triggering its translocation outside the nucleus (8), thereby 
antagonizing the anti-fibrotic program (9) that Foxo1 maintains in physiology. Activation of 
Gi by GIV's GEF function (2) inhibits the production of cAMP (10), a major anti-fibrotic 
pathway in HSCs by virtue of its ability to inhibit HSC migration and proliferation (11). The 
cAMP-PKA pathway is also known to inhibit fibrosis at a transcriptional level by 
phosphorylating CREB (12) which translocates to the nucleus and inhibits transcription of 
collagen and α-SMA (13). Pro-fibrogenic pathways = blue; Anti-fibrogenic = red.
Lopez-Sanchez et al. Page 36
Nat Commun. Author manuscript; available in PMC 2015 January 21.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Figure 9. GIV expression in liver biopsies may predict fibrogenic progression
(A) GIV expression was analyzed in liver biopsies from normal subjects and a cohort of 
HCV-infected patients at various stages of fibrosis by IHC. Staining was scored by two 
pathologist blinded to the degree of fibrosis using a simple binary scoring system; i.e., 
positive or negative for GIV. Results are displayed as % patients positive for GIV (Y axis) 
in each category of fibrosis.
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(B) Representative IHC images from A are displayed showing examples of positive and 
negatively-stained liver samples within different categories of fibrosis. Magnification = 
10X.
(C, D) Line plots depict the progression of fibrosis in patients with no or minimal fibrosis, 
as determined using FIB-4 (C) and APRI (D) scores derived from clinical parameters at the 
time of liver biopsy and at 3 yr follow-up. p values indicate significant differences in 
fibrosis scores at 3 yr.
(E) Schematic shows our proposed model for GIV's role in fibrogenic signaling in HSCs 
during liver fibrosis. Top to Bottom: Fibrogenic injuries of various kinds result in the 
activation of diverse classes of receptors that trigger upregulation of GIV in HSCs. 
Increased GIV triggers transformation of quiescent HSCs into activated myofibroblasts by 
modulating two key signaling pathways: 1) the pro-fibrotic PI3-KAkt pathway and, 2) the 
anti-fibrotic cAMP-PKA pathway. In quiescent HSCs low levels of GIV expression generate 
a net antifibrogenic signaling program characterized by low Akt activity and impaired 
activation of Gαi with resultant high levels of cAMP. In activated HSCs high levels of GIV 
expression generate a net profibrogenic signaling program characterized by high Akt activity 
and increased activation of Gαi with resultant low levels of cAMP. Low GIV expression 
maintains HSCs in quiescent state, triggers apoptosis, and suppresses collagen production in 
the normal liver, whereas high GIV expression enhances HSC migration, proliferation, and 
survival, and triggers collagen production, thereby leading to liver fibrosis. n = number of 
patients. Error bars represent mean ± S.D. Statistical significance was assessed with two-
tailed Student's t test.
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